House Passes 2026 Farm Bill With Hemp Product Ban Intact as Senate Battle Looms
The clock is ticking for a $28 billion industry as the legislation moves to a Senate where bipartisan resistance is building.
By CBDWorldNews Editorial Staff | May 12, 2026
The U.S. House voted 224-200 on April 30 to pass the Farm, Food, and National Security Act of 2026, sending a massive agriculture spending package to the Senate with one of the most controversial hemp provisions in the industry’s history still attached. The bill keeps the restrictive hemp product language from last year’s continuing resolution fully intact, setting up a high-stakes fight in the upper chamber.
What the Bill Does to Hemp
The core problem for the hemp industry sits in Section 781 of the Continuing Appropriations and Extensions Act, signed by President Trump on November 12, 2025. That provision rewrites the federal definition of hemp, shifting compliance from delta-9 THC alone to total THC content. More critically, it imposes a hard cap of 0.4 milligrams of total THC per finished product container.
That threshold is so low that the U.S. Hemp Roundtable estimates it would eliminate roughly 95% of hemp-derived cannabinoid products currently on the market. The new rules take effect November 12, 2026, giving the industry just six months to adapt or shut down.
The House-passed Farm Bill does offer one concession to the broader hemp farming community. It directs the USDA to reduce or eliminate testing requirements and background checks for industrial hemp producers, easing paperwork for farmers growing fiber and grain varieties. But it does nothing to soften the product ban.
The Senate Wild Card
The legislation now moves to a Senate where the dynamics look different. Sen. Rand Paul (R-KY) filed the bipartisan Hemp Safety Enforcement Act on April 16 alongside Sen. Amy Klobuchar (D-MN) and Sen. Joni Ernst (R-IA). Their bill would let states and tribal governments opt out of the federal ban entirely by submitting a notification through their state agriculture department.
States that opt out would need to enforce a minimum purchase age and maintain the ban on synthetic cannabinoids. They would also gain protection for interstate commerce of hemp products between participating states.
Paul framed the bill as a states’ rights issue during its introduction. Kentucky alone employs thousands in hemp processing and manufacturing, and the senator has positioned himself as the industry’s primary advocate in the upper chamber.
“The hemp sector faces extinction because of a provision buried in an appropriations bill that most members of Congress never read before voting on it.”
The Numbers at Stake
Industry groups have laid out the economic damage in stark terms. The hemp-derived product market generates $28.4 billion in annual economic activity across the United States. It supports an estimated 320,000 jobs. State and local governments collect roughly $1.5 billion in tax revenue from hemp businesses each year.
A full enforcement of the November deadline would wipe out the vast majority of that activity overnight. Small businesses, which make up the bulk of the hemp product supply chain, would bear the heaviest losses.
What Happens Next
The Senate has not yet scheduled committee hearings on its version of the Farm Bill. Agricultural policy observers expect the hemp provisions to generate significant debate, particularly given the bipartisan coalition backing Paul’s opt-out approach.
The Trump administration added a layer of complexity in early May when the White House Office of National Drug Control Policy released its 2026 National Drug Control Strategy. The document calls for a whole-of-government approach to crack down on unregulated psychoactive hemp derivatives, particularly delta-8 THC. That language suggests the executive branch will not push Congress to soften the product restrictions.
For hemp businesses, the path forward depends entirely on what the Senate does between now and November. If Paul’s bill gains traction, states with established hemp industries could preserve their markets through the opt-out mechanism. If the Senate passes the Farm Bill without changes to the hemp language, the November 12 deadline stands.
Industry Response
The U.S. Hemp Roundtable and allied trade groups are mobilizing for what they describe as the most consequential legislative fight in the industry’s modern history. Their strategy centers on three goals: building Senate support for Paul’s opt-out bill, lobbying for a delay to the November implementation date, and pushing for a total THC threshold that reflects realistic product formulations.
CBD product manufacturers who rely on third-party lab testing and transparent COAs argue that the industry already has the tools to self-regulate effectively. Many established brands have voluntarily adopted testing standards that go beyond current federal requirements.
The next several weeks will determine whether the hemp industry survives in anything close to its current form or contracts to a fraction of its size by year’s end.
These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease.
